People: Wuxi Pharmatech Cayman Inc (WX)

WX on New York Consolidated

36.39USD
23 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$36.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
360,500
52-wk High
$40.72
52-wk Low
$28.57

Search Stocks

Summary

Name Age Since Current Position

Ge Li

47 2004 Chairman of the Board, Chief Executive Officer

Edward Hu

51 2014 Chief Financial Officer, Chief Investment Officer

Steve Yang

2014 Chief Operating Officer, Executive Vice President

Xiaozhong Liu

50 2005 Executive Vice President, Director

Zhaohui Zhang

44 2013 Senior Vice President - Operations, Head - Domestic Marketing, Director

Ning Zhao

47 2013 Director, Senior Vice President - Operations, Head of Corporate Human Resources

Hua Mu

2014 Senior Vice President - Operations and Global Head of the Product Development Service and Partnership Business Unit

Shuhui Chen

50 2004 Chief Scientific Officer

Alexander Fowkes

44 2012 Vice President - Corporate Development

Suhan Tang

47 2007 Chief Manufacturing Officer

Stewart Hen

2009 Independent Director

William Keller

2014 Independent Director

Teh Ming Kwauk

61 2014 Independent Director

Xuesong Leng

44 2008 Independent Director

Kian Wee Seah

51 2005 Independent Director

Ronald Aldridge

IR Contact

Biographies

Name Description

Ge Li

Dr. Ge Li, Ph.D., is Chairman of the Board, Chief Executive Officer of WuXi Pharmatech (Cayman) Inc. Dr. Li is one of the founders of our company. He is responsible for operations, strategic planning and business development. He was one of the founding scientists of Pharmacopeia, Inc. He received a bachelor’s degree in chemistry from Peking University and a master’s degree and a Ph.D. in organic chemistry from Columbia University. Dr. Li’s wife, Dr. Ning Zhao, serves as one of our directors, senior vice president of operations, and head of corporate human resources.

Edward Hu

Mr. Edward Hu is Chief Financial Officer, Chief Investment Officer of WuXi PharmaTech (Cayman) Inc. He has served as the Company's Chief Operating Officer since January 2008 and as Chief Financial Officer since February 2009. He spearheaded efforts to build many of the company's new businesses, including biologics, toxicology, genomics, and clinical trial services in China. He led the acquisition and integration of AppTec, Abgent, and MedKey. He also created and has managed WuXi's joint ventures with MedImmune to co-develop an innovative biologics product in China, and with PRA to create a clinical CRO in China that meets the highest international standards. He received his MBA and completed his Ph.D. work, except for his dissertation, in biophysics and biochemistry at Carnegie Mellon University.

Steve Yang

Dr. Steve Yang is Chief Operating Officer, Executive Vice President of WuXi PharmaTech (Cayman) Inc. Dr. Yang is a pharmaceutical industry leader recognized for building R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. He and his team transformed the mission of AstraZeneca Innovation Center China, delivered AstraZeneca's first preclinical drug candidate discovered in China, strengthened translational science capabilities, established research outsourcing strategic partnerships, and facilitated and managed a series of scientific collaborations in China, Russia, Israel, Taiwan, and Korea. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer's global R&D strategic management group based in the United States. Before joining Pfizer, Dr. Yang held a number of leadership positions at IntraBiotics Pharmaceuticals, a U.S.-based biotech company. He also worked for Strategic Decisions Group, a strategy consulting firm for Fortune 100 companies. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as Chairman for two terms.

Xiaozhong Liu

Mr. Xiaozhong Liu is Executive Vice President and Director of WuXi PharmaTech (Cayman) Inc. Mr. Liu is one of the founders of our company. He is responsible for our project and engineering departments. Mr. Liu received a bachelor’s degree from Peking University and an EMBA from China Europe International Business School.

Zhaohui Zhang

Mr. Zhaohui Zhang is Senior Vice President - Operations, Head - Domestic Marketing, Director of WuXi PharmaTech (Cayman) Inc. Prior to joining our company, he worked for Jiangsu Silver Bell Group as an Assistant to the General Manager and later as a Vice President of American Silver Bell Company responsible for government procurement. Mr. Zhang received a bachelor’s degree in mechanical and electrical engineering from Jiangnan University.

Ning Zhao

Dr. Ning Zhao, Ph.D., is Director, Senior Vice President - Operations, Head of Corporate Human Resources of WuXi PharmaTech (Cayman) Inc., since February 2009. Dr. Zhao, one of company’s co-founders , is currently Senior Vice President of Operations and Head of Corporate Human Resources. She was Vice President of the company’s analytical services department from 2004 to 2008 and also established its bioanalytical services, core analytical services and analytical development services departments. Dr. Zhao has previously worked for Wyeth, Pharmacopeia and Bristol-Myers Squibb. She received a bachelor’s degree in chemistry from Peking University and a Ph.D. in chemistry from Columbia University.

Hua Mu

Dr. Hua Mu is Senior Vice President - Operations and Global Head of the Product Development Service and Partnership Business Unit of WuXi PharmaTech (Cayman) Inc. Dr. Mu has over 18 years of clinical research and development experience, having held medical and clinical leadership positions with several global pharmaceutical and biotech companies, including Roche, Abraxis Bioscience (now Celgene), Biogen Idec, Genentech, and Procter and Gamble. Dr. Mu's responsibilities have included early- to late-stage development of cytotoxic agents, small molecules, and monoclonal antibodies; management of clinical and regulatory organizations; creation and oversight of external collaborations and partnerships; interaction with regulatory authorities in the United States, Europe and Asia; and advancement of drug candidates to market and through their post-market development. Before joining WuXi, Dr. Mu was the Executive Vice President and Chief Medical Officer at Hutchison MediPharma, a company that in four years has successfully obtained five IND approvals and one Phase II/III CTA approval from the China Food and Drug Administration and advanced six compounds into various stages of clinical development. Dr. Mu received his medical degree from West China University of Medical Sciences and a Ph.D. in epidemiology from the University of California at Berkeley, under the mentorship of Dr. Mary-Claire King, a renowned cancer geneticist and the discoverer of the breast cancer BRCA gene. Earlier in his career, Dr. Mu was a Senior Fellow at the Schools of Medicine of the University of California in San Francisco and the University of Washington, where he conducted translational research on autoimmune diseases and breast cancer.

Shuhui Chen

Dr. Shuhui Chen Ph.D., is Chief Scientific Officer of WuXi PharmaTech (Cayman) Inc. Dr. Chen’s main responsibilities include overseeing our laboratory services segment in China. From 1998 to 2004, he worked for Eli Lilly as a Research Advisor. From 1995 to 1997, he worked for Vion Pharmaceuticals as a Group Leader and later as an Associate Director of Chemistry on several anti-cancer and anti-viral projects. From 1990 to 1995, he worked for Bristol-Myers Squibb as a Research Investigator and later as a Senior Research Investigator. Dr. Chen received a bachelor’s degree in chemistry from Fudan University and a Ph.D. in organic chemistry from Yale University.

Alexander Fowkes

Alexander Fowkes has served as our Vice President of Corporate Development of WuXi PharmaTech (Cayman) Inc., since July 2012. Prior to joining our company, he worked at Pfizer for 13 years in various leadership roles supporting R&D in the UK, Australia, U.S. and, most recently, China. From 2006 to 2011, he served as Executive Director and Head of Asia R&D Business Development & Operations at Pfizer, supporting and leadding the establishment of Pfizer’s research operations in China and its team of external research professionals throughout Asia Pacific. Mr. Fowkes received a bachelor’s degree in biochemistry and pharmacology from the University of Queensland and a bachelor’s degree in law from Bond University.

Suhan Tang

Dr. Suhan Tang is Chief Manufacturing Officer of WuXi PharmaTech (Cayman) Inc. Dr. Tang has served as Chief Manufacturing Officer since 2007. Dr. Tang’s main responsibilities include overseeing manufacturing services segment. From 2003 to 2006, he was Vice President of Process Research and Development. From 1996 to 2003, he worked for Schering-Plough as a Principal Scientist. Dr. Tang received a bachelor’s degree in chemistry from Jilin University and a master’s degree and a Ph.D. in organic chemistry from Columbia University.

Stewart Hen

Mr. Stewart J. Hen is Independent Director of WuXi PharmaTech (Cayman) Inc., since February 2009. Since August 2010, Mr. Hen has been Managing Partner of Serrado Capital LLC, a healthcare investment firm based in New York. Previously, he was a Managing Director at Warburg Pincus LLC where he focused on investments in biotechnology and pharmaceuticals. He has more than 18 years of experience in the life sciences industry. Prior to joining Warburg Pincus in 2000, he was a consultant at McKinsey & Company serving the pharmaceutical industry. From 1990 to 1994, he worked at Merck in both research and development and manufacturing. Mr. Hen received an MBA from the Wharton School of the University of Pennsylvania and a master’s degree in chemical engineering from the Massachusetts Institute of Technology.

William Keller

William Robert Keller has been appointed as Independent Director of WuXi PharmaTech (Cayman) Inc. Mr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2003, and he served in various positions at Roche Group in South America and Asia from 1974 to 2003. He has been the vice chairman of the Shanghai Association of Enterprises with Foreign Investment, a senior consultant to the Shanghai Foreign Investment Development Board, and the deputy general manager of Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. Mr. Keller currently holds directorships at Alexion Pharmaceuticals, Inc. Coland Pharmaceutical Co., Ltd.and Cathay Industrial Biotech Ltd. and previously served as an independent director of China Nuokang Bio-Pharmaceutical Inc. and Shanghai Fosun Pharmaceutical Co., Ltd. (hk:02196). He is the founder, and since September 2003 a principal, of Keller Pharma Consultancy, a pharmaceutical consulting firm in China. He has also served as a supervisor of TaiGen Biotechnology Co., Ltd., and as chairman of HBM Biomed China Partners. Mr. Keller graduated from the School of Economics and Business Administration in Zurich. He is an honorary citizen of the city of Shanghai.

Teh Ming Kwauk

Mr. Teh-Ming Kwauk is an Independent Director of the Company. Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co., Ltd. He serves as a director of Thunder Power Co. Ltd.; Sinosoft Technology Group Ltd., of which he serves as chairman of the audit committee; China Fordoo Holdings Ltd., of which he serves as chairman of the audit committee; and several private companies. He was formerly a director of Alibaba.com Ltd. Mr. Kwauk worked for KPMG from 1977 to 2002 and held a number of senior positions, including the general manager of KPMG's joint venture accounting firm in Beijing, the managing partner in KPMG's Shanghai office, and a partner in KPMG's Hong Kong office. He is a member of the Hong Kong Institute of Certified Public Accountants. Mr. Kwauk received a B.S. and a licentiate's degree in accounting from the University of British Columbia.

Xuesong Leng

Mr. Xuesong Leng is Independent Director of WuXi PharmaTech (Cayman) Inc. Mr. Leng joined General Atlantic LLC, a global growth investor, as Managing Director in 2007. From June 1999 to September 2007, he served as a Managing Director, Vice President and Associate at Warburg Pincus. Mr. Leng holds a bachelor’s degree from the business school of Jiao Tong University in Shanghai and an MBA from the Wharton School of the University of Pennsylvania.

Kian Wee Seah

Mr. Kian Wee Seah is Independent Director of WuXi PharmaTech (Cayman) Inc. Mr. Seah joined UOB Venture Management Pte. Ltd. in 1997 and currently holds the position of Managing Director. He chairs the investment committees of several private equity funds that focus on growth companies in China and ASEAN. He is a Chartered Financial Analyst. Mr. Seah received a bachelor’s degree in engineering from National University of Singapore, a master’s degree from the University of California at Los Angeles and an EMBA from Tsinghua University.

Ronald Aldridge

Search Stocks